Company profile for Iovance Biotherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was initially developed by Dr. Steven A. Rosenberg at the National Cancer Institute (NCI). In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology were reported by NCI to have...
Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was initially developed by Dr. Steven A. Rosenberg at the National Cancer Institute (NCI). In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology were reported by NCI to have achieved objective and complete response criteria, respectively. Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrate

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
999 Skyway Road Suite 150 San Carlos, CA 94070
Telephone
Telephone
650-260-7120
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/21/3193043/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
21 Nov 2025

https://www.globenewswire.com/news-release/2025/10/23/3172446/0/en/Iovance-Biotherapeutics-to-Host-Third-Quarter-2025-Financial-Results-and-Corporate-Updates-Webcast-on-Thursday-November-6-2025.html

GLOBENEWSWIRE
23 Oct 2025

https://www.globenewswire.com/news-release/2025/10/17/3168919/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
17 Oct 2025

https://www.globenewswire.com/news-release/2025/09/19/3153442/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
19 Sep 2025

https://www.globenewswire.com/news-release/2025/08/29/3141472/0/en/Iovance-Biotherapeutics-to-Present-at-Upcoming-Conferences.html

GLOBENEWSWIRE
29 Aug 2025

https://www.globenewswire.com/news-release/2025/08/22/3138052/0/en/Iovance-Biotherapeutics-Reports-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
22 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty